Welcome to our dedicated page for Avantor SEC filings (Ticker: AVTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Avantor, Inc. (NYSE: AVTR) SEC filings, offering a view into the company’s financial reporting, governance updates and material events. Avantor is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries, and its regulatory filings document key aspects of this business.
Through Forms 10-K and 10-Q, readers can review Avantor’s audited annual and quarterly financial statements, along with management’s discussion of results, risk factors and segment information. Current reports on Form 8-K capture material developments such as quarterly earnings announcements, leadership and board changes, amendments to credit facilities, and other significant transactions. For example, recent 8-K filings describe the appointment of a new President and Chief Executive Officer, the creation of an Executive Vice President and Chief Operating Officer role, the election of new independent directors, and amendments to senior secured credit facilities and the termination of an accounts receivable securitization facility.
Avantor’s filings also explain the company’s use of non-GAAP financial measures, including Adjusted Operating Income, Adjusted EBITDA, adjusted net income, adjusted EPS, adjusted net leverage, free cash flow and free cash flow conversion, and provide reconciliations to comparable GAAP measures. Investors can use these disclosures to understand how management evaluates performance and capital structure.
On this page, Stock Titan pairs real-time EDGAR updates with AI-powered summaries that highlight the main points in each filing. Users can quickly identify items related to quarterly results, financing arrangements, governance changes and other topics, while still having access to the full original documents for detailed review.
Avantor, Inc. director Simon Dingemans reported an open-market purchase of 25,000 shares of Common Stock. The trade was executed at a price of $8.14 per share and is reported as indirect ownership "By Spouse", meaning the shares are held by his spouse but attributed to him for reporting.
The filing also shows Dingemans with 6,225 shares of Common Stock held directly as of the same date in a separate holding entry. There are no derivative securities reported, so this update reflects only common stock ownership.
Avantor, Inc. executive Ludovic Brellier, EVP, Bioscience & Medtech, received new equity awards. He was granted 146,566 shares of common stock in the form of restricted stock units that vest in three equal annual installments beginning on May 1, 2027. Following this grant, he holds 146,566 common shares directly. He also received 246,002 stock options to buy common stock at an exercise price of $8.76 per share, which vest in three equal annual installments starting on May 1, 2027 and expire on May 1, 2036. These awards are part of his compensation, not open-market purchases or sales.
Avantor, Inc. executive Ludovic Brellier, EVP of Bioscience & Medtech, has filed an initial Form 3 reporting his status as an insider. The provided data shows no buy, sell, or other share transactions and no derivative positions reported in this filing excerpt.
Avantor Inc reported that Vanguard Capital Management beneficially owns 35,802,263 shares of Common Stock, equal to 5.29% of the class. The filing states Vanguard Capital Management has sole dispositive power over 35,802,263 shares and sole voting power over 5,196,151 shares.
The disclosure names affiliated Vanguard entities that exercise voting or dispositive power for certain holdings and is signed by Ashley Grim, Head of Global Fund Administration.
Avantor reported mixed first-quarter 2026 results with weaker profitability but steady sales and reaffirmed guidance. Net sales were $1,581.4 million, flat with a year earlier, while foreign currency tailwinds meant organic net sales declined 4.1%.
Net income fell to $43.3 million from $64.5 million, and diluted GAAP EPS declined to $0.06 from $0.09. Adjusted net income was $114.0 million versus $155.2 million, with adjusted EPS down to $0.17 from $0.23 and adjusted EBITDA decreasing to $219.4 million, a 13.9% margin versus 17.0%.
Segment results showed lower adjusted operating income in both VWR Distribution & Services and Bioscience & Medtech Products. Operating cash flow was $58.7 million compared with $109.3 million, and free cash flow was $25.2 million versus $82.1 million. As of March 31, 2026, adjusted net leverage was 3.3x. The company reaffirmed its full-year 2026 financial guidance.
Avantor, Inc. announced a leadership transition in its Bioscience & Medtech Products segment. The company hired Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products and Chief Transformation Officer, effective May 1, 2026, to lead growth, operational performance and the Revival Management Office.
The current Executive Vice President, Bioscience and Medtech Products, Benoit Gourdier, will move into a role supporting segment integration activities and is expected to depart the company no later than December 31, 2026. The changes focus on business transformation and integration across Avantor’s enterprise.
Eck Steven W reported acquisition or exercise transactions in this Form 4 filing.
Avantor, Inc. reported that SVP & Chief Accounting Officer Steven W. Eck received an equity grant in the form of restricted stock units. He was awarded 31,645 shares of Common Stock at a stated price of $0.00 per share, reflecting a compensation grant rather than an open-market purchase.
The restricted stock units vest in three equal annual installments beginning on April 3, 2027, tying the award to multi‑year service. After this grant, Eck directly holds 130,978 shares of Avantor common stock, showing his ongoing equity stake in the company.
Avantor, Inc. announced a planned CFO transition and reaffirmed its fiscal 2026 guidance. Executive Vice President and CFO R. Brent Jones will leave the company on or before June 24, 2026, after providing 90 days’ notice under his employment agreement unless waived.
Upon his departure, Senior Vice President and Chief Accounting Officer Steve Eck will serve as interim CFO while continuing as principal accounting officer as the company conducts a search for a permanent CFO. To reflect his expanded responsibilities, Eck will receive an additional $45,000 per month for each month he serves as interim CFO and a one-time $250,000 restricted stock unit award vesting ratably over three years.
The company highlighted Eck’s extensive finance and accounting background and stated that its previously issued fiscal 2026 financial guidance from its fourth quarter 2025 earnings call remains unchanged.